Outbreak of Ralstonia mannitolilytica Infection in Hemato-Oncology Unit: Case Series and Review of Literature
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(02): 201-207
DOI: DOI: 10.1055/s-0042-1742448
Abstract
Ralstonia mannitolilytica is a Gram-negative, nonfermentative, soil bacterium that is reported to cause opportunistic infections in immunocompromised patients in nosocomial settings. After extensive review of literature, it was found that this is second outbreak reported from India. This study is a retrospective analysis of the clinical features, outcome, and source identification of R. mannitolilytica infection outbreak in a hemato-oncology unit of a tertiary care center of North India between February 2020 and March 2020. We report an outbreak of R. mannitolilytica bacteremia (with or without septic shock) in five patients admitted in hemato-oncology unit at a tertiary care institute in North India for 1 month period. Four patients were cured after administration of appropriate antibiotics as per sensitivity reports, while one patient died of septicemia due to delayed diagnosis. Environmental cultures revealed multidose saline bottles used for administration of drugs as the source of outbreak. Following implementation of use of single dose diluents and flushing solutions in patients with central venous catheter, no new case was reported. Clinicians and microbiologists should keep high index of suspicion to identify these organisms as timely diagnosis is the only key to improve outcomes.
Publication History
Article published online:
08 March 2022
© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
Abstract
Ralstonia mannitolilytica is a Gram-negative, nonfermentative, soil bacterium that is reported to cause opportunistic infections in immunocompromised patients in nosocomial settings. After extensive review of literature, it was found that this is second outbreak reported from India. This study is a retrospective analysis of the clinical features, outcome, and source identification of R. mannitolilytica infection outbreak in a hemato-oncology unit of a tertiary care center of North India between February 2020 and March 2020. We report an outbreak of R. mannitolilytica bacteremia (with or without septic shock) in five patients admitted in hemato-oncology unit at a tertiary care institute in North India for 1 month period. Four patients were cured after administration of appropriate antibiotics as per sensitivity reports, while one patient died of septicemia due to delayed diagnosis. Environmental cultures revealed multidose saline bottles used for administration of drugs as the source of outbreak. Following implementation of use of single dose diluents and flushing solutions in patients with central venous catheter, no new case was reported. Clinicians and microbiologists should keep high index of suspicion to identify these organisms as timely diagnosis is the only key to improve outcomes.
Introduction
Ralstonia mannitolilytica is an aerobic, Gram-negative, nonfermenting bacterium that has been classified as one of the emerging opportunistic pathogens globally. It survives well in low-nutrient conditions and is found commonly residing in water and soil.[1] Infections with this organism are often nosocomial (hospital acquired), affecting mainly immunocompromised hosts.[2] Ralstonia spp is reported to cause serious infections such as sepsis, meningitis, and pneumonia mainly in hospital setting.[3] [4] [5] [6] [7] The progression of infection is rapid and early identification of the organism and treatment with appropriate antibiotics is the key to prevent adverse outcome ([Table 1]).
Ref no. |
Year |
Country |
Sex/age (in years) |
No. of cases |
Comorbidity/primary disease |
Type of infection/CVC |
Antibiotic sensitivity |
Antibiotic resistance |
Antibiotic treatment |
Outcome |
---|---|---|---|---|---|---|---|---|---|---|
[11] |
1972 |
UK |
Multiple |
40 |
Various |
Bacteremia and bacteriuria CVC—N/A |
Trimethoprim sulfonamides, tetracycline, cephalexin |
Polymyxin Gentamicin, carbenicillin |
N/A |
Complete recovery |
5 |
2001 |
Belgium |
F/38 |
2 |
Hydrocephalu s |
Meningitis Ventriculoatrial catheter |
Cotrimoxazole, piperacillin, imipenem, cefuroxime, cefotaxime, ceftazidime, and quinolones |
Temocillin, aztreonam ampicillin, gentamicin |
Co-trimoxazole and doxycycline |
Complete recovery |
F/32 |
Cholangiocarci noma |
Peritoneal infection Kehr drain |
Cotrimoxazole, cefuroxime and quinolones |
Ampicillin, gentamicin, colimycin, temocillin |
Cefuroxime, metronidazole |
Complete recovery |
||||
[12] |
2003 |
India |
M/14 |
1 |
Post renal transplant |
Bacteremia CVC—present |
Cefuroxime, ceftriaxone, cefotaxime cefoperazone—sulbactam, ampicillin, ampicillin—sulbactam, amoxicillin, amoxicillin—clavulanic acid, piperacillin |
Amikacin, gentamicin cephalexin, ceftazidime, ciprofloxacin |
Ciprofloxacin, amikacin—no response cefoperazone–sulbactam |
Cured |
[13] |
2005 |
Austria |
Multiple patients |
26 |
Various |
Bacteremia CVC—N/A |
Cefepime, ciprofloxacin |
Gentamicin, amikacin, imipenem, piperacillin–tazobactam |
N/A |
2 Deaths, complete cure in others |
11 |
2007 |
USA |
Multiple patients |
38 |
Various (pediatric patients) |
Respiratory infections including pneumonia CVC—N/A |
N/A |
N/A |
N/A |
1 Death, complete cure in others |
6 |
2007 |
Germany |
Multiple |
5 |
Cancer |
Bacteremia CVC—N/A |
Ampicillin–sulbactam, piperacillin, piperacillin– tazobactam, cefuroxime, cefotaxime, co-trimoxazole, levofloxacin, ciprofloxacin |
Meropenem, gentamicin, tobramycin, ampicillin |
N/A |
Complete recovery |
[14] |
2011 |
China |
M/78 |
1 |
Type 2 DM COPD |
Respiratory infection CVC—N/A |
Levofloxacin, ciprofloxacin ceftriaxone, piperacillin–tazobactam, imipenem, trimethoprim–sulfamethoxazole |
Amoxicillin–clavulanic acid, ampicillin–sulbactam, ticarcillin–clavulanic acid Gentamicin, amikacin, ceftazidime, ampicillin, tobramycin, piperacillin, cefazolin, cefoxitin |
Piperacillin- tazobactam |
Death |
[15] |
2012 |
Greece |
F/6 |
1 |
On peritoneal dialysis for ESRD |
Peritonitis CVC—N/A |
Levofloxacin cefepime ceftazidime, ciprofloxacin, imipenem |
Aztreonam, colistin, meropenem |
Failed co- trimoxazole f/b vancomycin and ceftazidime |
Complete recovery |
7 |
2013 |
Israel |
Neonate |
1 |
Prematurity |
Bacteremia |
N/A |
Ampicillin, gentamicin, cefotaxime, meropenem |
Initially ampicillin, cefotaxime, gentamicin |
Complete recovery |
Failure then upgraded to co-trimoxazole |
||||||||||
[16] |
2016 |
China |
F/74 |
3 |
Gastric T cell lymphoma, HTN, DM |
Bacteremia/CVC present |
Co-trimoxazole, ceftriaxone, piperacillin–tazobactam, ampicillin—sulbactam |
Gentamycin, amikacin, cefepime, imipenem, ampicillin, cefazolin |
Piperacillin–tazobactam |
Complete recovery |
M/56 |
Gastric carcinoma |
Bacteremia/CVC—present |
Piperacillin–tazobactam |
|||||||
F/55 |
Hepatic hemangioma, HTN, DM |
Bacteremia |
Piperacillin–tazobactam |
|||||||
[17] |
2016 |
Canada |
F/39 |
2 |
Cystic fibrosis |
Pneumonia, septi c shock, lung abscess CVC—N/A |
N/A |
Resistant to all antibiotics on antibiogram |
Multiple iv antibiotic combinations |
Death |
F/19 |
Pneumonia, septic shock CVC—N/A |
Piperacillin-tazobactam |
Death |
|||||||
8 |
2017 |
Japan |
F/65 |
1 |
ESRD on dialysis, DM, HTN, ischemic heart disease |
Bacteremia/CVC—present |
Ceftazidime, piperacillin—tazobactam |
Amikacin, gentamicin, meropenem, polymyxin |
Ceftazidime |
Complete recovery |
10 |
2017 |
Rome |
Multiple |
22 |
Solid cancer |
Bacteremia/ CVC all patients |
Piperacillin–tazobactam |
Gentamicin, amikacin, ciprofloxacin, meropenem, ceftazidime |
N/A |
Complete recovery |
9 |
2018 |
India |
M/70 |
4 |
ESRD on dialysis, HTN, hypothyroid |
Bacteremia, shock /tunneled catheter |
Ciprofloxacin, levofloxacin, cefoperazone—sulbactam, cefepime, co-trimoxazole |
Gentamicin, amikacin, meropenem, imipenem, aztreonam |
Cefoperazone–sulbactam |
Complete recovery |
M/36 |
ESRD on dialysis, HTN |
Bacteremia, shock/right IJV HD catheter |
Ciprofloxacin |
Complete recovery |
||||||
F/50 |
HTN, DM, hypothyroid |
Bacteremia/right IJV HD catheter |
Cefepime |
Complete recovery |
||||||
F/32 |
ESRD on dialysis, HTN |
Bacteremia/tunneled catheter |
Levofloxacin |
Complete recovery |
||||||
[18] |
2019 |
Italy |
F/46 |
H/o breast implants, thyroidectomy/post carotid artery aneurysm clipping |
Bacteremia |
Ciprofloxacin, levofloxacin, piperacillin—tazobactam, piperacillin, co-trimoxazole |
Amikacin, gentamicin, tobramycin, meropenem, imipenem, ertapenem, ceftazidime, cefepime, aztreonam |
Ciprofloxacin, co-trimoxazole |
Complete recovery |
Patient 1 |
Patient 2 |
Patient 3 |
Patient 4 |
Patient 5 |
|
---|---|---|---|---|---|
Age(y) |
36 |
4 |
5 |
67 |
5 |
Gender |
Female |
Male |
Male |
Male |
Female |
Underlying disease |
AML |
Thalassemia undergoing MSD allogenic SCT |
Refractory ALL |
B cell NHL |
AML |
Prior chemotherapy |
Daunorubicin+ cytarabine |
Bu+ Cy+ Flu+ ATG based conditioning |
FLAG-IDA Regimen |
R-CHOP regimen |
AIE |
Clinical features |
Respiratory distress, fever |
High-grade fever |
High-grade fever |
High-grade fever, altered sensorium |
High-grade fever |
Vascular access |
PICC line |
Hickmann catheter |
Port-a-cath |
PICC line |
Port-a-cath |
Days from CVP insertion |
28 |
8 |
94 |
15 |
7 |
Positive culture site |
Peripheral |
CVC |
Peripheral |
PICC line |
Port-a-cath |
Hb g/dL |
8.0 |
8.2 |
9 |
8.9 |
8.4 |
TLC/ANC/µl |
200 |
1100/600 |
1400/340 |
18,350/12,000 |
2300/1250 |
Platelets/mm3 |
11,000 |
90,000 |
69,000 |
10,4000 |
1,14,000 |
Procalcitonin ng/mL |
16 |
0.4 |
5.6 |
56 |
1.2 |
Antibiotic sensitivity |
Doxycycline, levofloxacin, co-trimoxazole, cefoperazone–sulbactam |
Ceftazidime, piperacillin–tazobactam, doxycycline, levofloxacin, co-trimoxazole, cefoperazone—sulbactam |
Ceftazidime, doxycycline, levofloxacin, co-trimoxazole, cefoperazone–sulbactam |
Piperacillin tazobactam, doxycycline, levofloxacin, co-trimoxazole, cefoperazone–sulbactam |
Doxycycline, levofloxacin, co-trimoxazole |
Therapeutic antibiotic |
Levofloxacin, co-trimoxazole |
Levofloxacin + cefoperazone—sulbactam |
Levofloxacin |
NA |
Levofloxacin |
Outcome |
Cured |
Cured |
Cured |
Death |
Cured |
References
- Yabuuchi E, Kosako Y, Yano I, Hotta H, Nishiuchi Y. Transfer of two Burkholderia and an Alcaligenes species to Ralstonia gen. Nov.: Proposal of Ralstonia pickettii (Ralston, Palleroni and Doudoroff 1973) comb. Nov., Ralstonia solanacearum (Smith 1896) comb. Nov. and Ralstonia eutropha (Davis 1969) comb. Nov. Microbiol Immunol 1995; 39 (11) 897-904
- Ryan MP, Adley CC. Ralstonia spp.: emerging global opportunistic pathogens. Eur J Clin Microbiol Infect Dis 2014; 33 (03) 291-304
- Boattini M, Bianco G, Biancone L, Cavallo R, Costa C. Ralstonia mannitolilytica bacteraemia: a case report and literature review. Infez Med 2018; 26 (04) 374-378
- Vaneechoutte M, De Baere T, Wauters G. et al. One case each of recurrent meningitis and hemoperitoneum infection with Ralstonia mannitolilytica. J Clin Microbiol 2001; 39 (12) 4588-4590
- Gröbner S, Heeg P, Autenrieth IB, Schulte B. Monoclonal outbreak of catheter-related bacteraemia by Ralstonia mannitolilytica on two haemato-oncology wards. J Infect 2007; 55 (06) 539-544
- Block C, Ergaz-Shaltiel Z, Valinsky L. et al. Déjà vu: Ralstonia mannitolilytica infection associated with a humidifying respiratory therapy device, Israel, June to July 2011. Euro Surveill 2013; 18 (18) 20471
- Lim CTS, Lee SE. A rare case of Ralstonia mannitolilytica infection in an end stage renal patient on maintenance dialysis during municipal water contamination. Pak J Med Sci 2017; 33 (04) 1047-1049
- Shankar M, Rampure S, Siddini V, Ballal HS. Outbreak of Ralstonia mannitolilytica in hemodialysis unit: a case series. Indian J Nephrol 2018; 28 (04) 323-326
- Lucarelli C, Di Domenico EG, Toma L. et al. Ralstonia mannitolilytica infections in an oncologic day ward: description of a cluster among high-risk patients. Antimicrob Resist Infect Control 2017; 6: 20
- Jhung MA, Sunenshine RH, Noble-Wang J. et al. A national outbreak of Ralstonia mannitolilytica associated with use of a contaminated oxygen-delivery device among pediatric patients. Pediatrics 2007; 119 (06) 1061-1068
- ;Dowsett E. Hospital infections caused by contaminated fluids. Lancet 1972; 1 (7764): 1338
- Mukhopadhyay C, Bhargava A, Ayyagari A. Ralstonia mannitolilytica infection in renal transplant recipient: first report. Indian J Med Microbiol 2003; 21 (04) 284-286
- Daxboeck F, Stadler M, Assadian O, Marko E, Hirschl AM, Koller W. Characterization of clinically isolated Ralstonia mannitolilytica strains using random amplification of polymorphic DNA (RAPD) typing and antimicrobial sensitivity, and comparison of the classification efficacy of phenotypic and genotypic assays. J Med Microbiol 2005; 54 (Pt 1): 55-61
- Zong ZY, Peng CH. Ralstonia mannitolilytica and COPD: a case report. Eur Respir J 2011; 38 (06) 1482-1483
- Dotis J, Printza N, Orfanou A, Papathanasiou E, Papachristou F. Peritonitis due to Ralstonia mannitolilytica in a pediatric peritoneal dialysis patient. New Microbiol 2012; 35 (04) 503-506
- Liu CX, Yan C, Zhang P, Li FQ, Yang JH, Li XY. Ralstonia mannitolilytica-induced septicemia and homology analysis in infected patients: 3 case Reports. Jundishapur J Microbiol 2016; 9 (07) e34373
- Coman I, Bilodeau L, Lavoie A. et al. Ralstonia mannitolilytica in cystic fibrosis: a new predictor of worse outcomes. Respir Med Case Rep 2016; 20: 48-50
- Basso M, Venditti C, Raponi G. et al. A case of persistent bacteraemia by Ralstonia mannitolilytica and Ralstonia pickettii in an intensive care unit. Infect Drug Resist 2019; 12: 2391-2395